Performance indicators | National Cancer Registry Ireland

Executive summary

Target not reached or not in line with other registries

Target attained

Indicator	UKIACR average (population)	UKIACR average (country)	England	Scotland	Wales	Northern Ireland	Republic of Ireland
Stability: Percentage change (%) for all cancers (C00-C97 ex. C44) in 2015 compared with 2012-2014	1.0%	0.4%	1.3%	-1.9%	-1.7%	1.6%	2.4%
Registry Creep: Percentage (%) for all cancers (C00-C97 ex. C44) of 2014 registrations at 31/01/2017 compared with registrations at 31/01/2016	1.3%	2.3%	1.0%	2.5%	2.6%	2.5%	2.7%
Staging: Proportion (%) of all cases (C00-C97 ex. C44) with valid known stage registered out of all 2015 registered cancers (C00-C97 ex. C44)	76.8%	69.4%	80.4%	60.8%	65.1%	82.4%	58.1%
Average of Core Patient Information Complete: Average percentage (%) of all cancers (C00-C97 ex. C44) registered with demographic information	98.2%	97.1%	98.9%	96.0%	91.0%	100.0%	99.6%
Average of Core Tumour Information Complete: Average percentage (%) of all cancers (C00-C97 ex. C44) registered with tumour information	97.2%	96.4%	97.5%	96.4%	94.3%	96.8%	97.2%
Diagnosing Hospital Known: Percentage (%) of all cancers (C00-C97 ex. C44) registered with an organisation of diagnosis	97.4%	96.1%	97.9%	93.2%	98.3%	95.5%	95.8%
Death Certificate Only (DCO) Rates: Percentage (%) of all cancers (C00-C97 ex. C44) registered as a DCO	0.7%	0.9%	0.7%	0.4%	1.7%	0.5%	1.0%
Zero Day Survivors: Percentage (%) of all cancers (C00-C97 ex. C44) registered with the date of death equals the date of diagnosis	1.4%	1.3%	1.5%	0.8%	2.2%	0.6%	1.6%
Microscopically Verified: Percentage (%) of all cancers (C00-C97 ex. C44) that are microscopically verified	85.4%	85.8%	85.4%	84.2%	80.4%	86.7%	92.1%
Non Specific Codes: Percentage (%) of all cancers (C00-C97 ex. C44) that are microscopically verified with non specific morphology codes	2.0%	3.7%	1.5%	1.5%	11.0%	1.5%	2.8%
Grade: Percentage (%) of all cancers (C00-C97 ex. C44) registered with a known grade	58.9%	55.1%	60.3%	58.5%	40.3%	61.0%	55.2%
Treatment: Percentage (%) of all cancers (C00-C97 ex. C44) registered with any treatment	83.3%	74.0%	87.5%	69.8%	57.3%	90.6%	64.8%
Breast Screening Data: Percentage of breast cancer (C50) cases from 2014 screen detected for ages 50-64	48.0%	50.7%	47.1%	48.1%	51.5%	51.4%	55.2%
Cervical Screening Data: Percentage of cervical cancer (C53) cases from 2014 screen detected for ages 25-60	19.2%	30.0%	13.8%	54.4%	NA	21.9%	NA
Bowel Screening Data: Percentage of bowel cancer (C18-C20) cases from 2014 screen detected for ages 60-69	18.8%	23.7%	17.0%	29.7%	21.2%	26.9%	NA

1B: Registrations and timeliness

Registrations and timeliness

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Wales	Northern Ireland	Republic of Ireland
2012	368966	73793	289371	31440	18451	9046	20658
2013	380497	76099	298808	31919	19690	9114	20966
2014	382412	76482	299847	32337	19839	9168	21221
2014 (from Previous PI)	377260	75452	296815	31541	19325	8936	20643
No. of 2015 not-finalised cases	358	72	336	22	0	0	0
No. of 2015 full cases	380964	76193	299969	31277	19004	9256	21458
Registry creep	1.3%	2.3%	1.0%	2.5%	2.6%	2.5%	2.7%
Not-finalised cases	0.1%	0.0%	0.1%	0.1%	0.0%	0.0%	0.0%

2: Ascertainment

No. of Cases (current year) and percentage change vs. previous year (persons)

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Wales	Northern Ireland	Republic of Ireland
All invasive xnmsc	380,964 (1%)	0.4%	299969 (1.3%)	31277 (-1.9%)	19004 (-1.7%)	9256 (1.6%)	21458 (2.4%)
All xnmsc 0-24	4,336 (3.3%)	2.9%	3417 (3.6%)	310 (6.7%)	205 (4.8%)	118 (5%)	286 (-5.5%)
All xnmsc 25-59	90,238 (1.8%)	0.6%	70178 (2.4%)	7346 (-2%)	4003 (-0.6%)	2364 (0.8%)	6347 (2.5%)
All xnmsc 60-79	203,814 (1.6%)	0.6%	159767 (2.1%)	17103 (-1.9%)	10521 (-2%)	4945 (1.8%)	11478 (2.8%)
All xnmsc 80+	82,576 (-1.5%)	-0.5%	66607 (-1.6%)	6518 (-2.3%)	4275 (-2.2%)	1829 (1.9%)	3347 (1.7%)
All registrations	632,493 (2.7%)	1.0%	493618 (3.4%)	52385 (-0.5%)	28808 (-1.7%)	17248 (0.4%)	40434 (3.6%)
Haematology	33,437 (1.3%)	2.0%	26871 (1.2%)	2371 (0.3%)	1704 (4%)	775 (3.7%)	1716 (0.8%)
Head and Neck	12,752 (5%)	5.9%	9733 (5.4%)	1280 (-0.6%)	685 (4.3%)	362 (12.2%)	692 (8.4%)
Lower GI	47,669 (0.3%)	-2.6%	37324 (1.2%)	3928 (-4%)	2408 (-5.9%)	1189 (-9%)	2820 (4.7%)
Upper GI	16,947 (0.4%)	-1.2%	13110 (1.1%)	1526 (-6.6%)	895 (0.9%)	404 (-7%)	1012 (5.7%)
HPB	18,816 (3.1%)	3.9%	14748 (3.1%)	1620 (1.8%)	968 (3.9%)	491 (9.5%)	989 (1.4%)
Trachea, Bronchus & Lung	48,723 (-0.6%)	-1.4%	37641 (0.3%)	4968 (-7.2%)	2448 (-0.7%)	1240 (0.8%)	2426 (-0.5%)
Melanoma	17,071 (8.9%)	9.9%	13356 (8.4%)	1358 (12.6%)	784 (0.5%)	402 (11.6%)	1171 (16.5%)
Breast	58,476 (2.8%)	4.5%	46100 (2.5%)	4753 (1.8%)	2836 (1%)	1468 (11.4%)	3319 (5.8%)
Cervix	3,366 (-3.3%)	-5.9%	2521 (-3.3%)	379 (12.6%)	150 (-10%)	81 (-13.5%)	235 (-15.4%)
Other Female Genitals	18,946 (-1.5%)	-2.1%	14940 (-1.2%)	1574 (-1%)	948 (-10.3%)	506 (0%)	978 (1.8%)
Prostate	50,239 (0.1%)	-1.5%	40310 (1.1%)	3052 (-6.2%)	2567 (-0.9%)	1133 (4.4%)	3177 (-5.9%)
Kidney	12,759 (2.9%)	-0.7%	10333 (4.3%)	924 (0.2%)	547 (-8.5%)	339 (6.7%)	616 (-6.3%)
Bladder	10,582 (-3%)	1.0%	8499 (-4%)	822 (-1.6%)	554 (-4.9%)	213 (1.9%)	494 (13.4%)
Brain and CNS	5,858 (1.2%)	-4.2%	4652 (3.2%)	412 (-9.2%)	278 (-4.9%)	137 (-8.5%)	379 (-1.6%)
Thyroid & other endocrine glands	4,138 (5.5%)	-2.4%	3343 (8.2%)	300 (4.9%)	125 (-10.7%)	87 (-4.4%)	283 (-10.2%)
CUP	9,132 (-5.3%)	-1.8%	7104 (-7%)	865 (0%)	524 (-4.6%)	163 (-19.3%)	476 (22.1%)
Other invasive cancer	12,053 (-2.4%)	-1.2%	9384 (-3.1%)	1145 (-1.1%)	583 (-6.4%)	266 (-7.1%)	675 (11.4%)
Breast in situ	8,342 (9.4%)	14.2%	6852 (9.6%)	466 (4.6%)	336 (-7%)	237 (54.9%)	451 (8.8%)
Cervix in situ	33,608 (-1.7%)	-2.6%	25034 (-1.5%)	2542 (-3%)	1734 (-15.4%)	1145 (-0.4%)	3153 (7.1%)
Other tumours	53,714 (-0.3%)	-0.8%	36536 (0.1%)	6236 (-3.4%)	3333 (7%)	2780 (-10.3%)	4829 (2.6%)
Other non-melanoma skin cancer	2371 (4.4%)	8.2%	1460 (-2.2%)	178 (18.9%)	481 (57.4%)	61 (-66%)	191 (32.9%)
Basal cell carcinoma	116078 (8.6%)	3.6%	95562 (9.8%)	8474 (5.6%)	2145 (-10.6%)	2715 (7.9%)	7182 (5.1%)
Squamous cell carcinoma	37500 (11.4%)	7.1%	28205 (13.4%)	3296 (8.1%)	1775 (2.1%)	1054 (7.6%)	3170 (4.3%)

3: % Death cert only

Percentage (%) of death certificate only cases (persons) for 2015

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Wales	Northern Ireland	Republic of Ireland
All invasive xnmsc	0.7%	0.9%	0.7%	0.4%	1.7%	0.5%	1.0%
All xnmsc 0-24	0.1%	0.2%	0.1%	0.0%	0.0%	0.0%	0.7%
All xnmsc 25-59	0.1%	0.1%	0.1%	0.1%	0.3%	0.1%	0.1%
All xnmsc 60-79	0.4%	0.5%	0.3%	0.3%	1.0%	0.4%	0.7%
All xnmsc 80+	2.3%	2.7%	2.2%	0.9%	5.0%	1.2%	4.0%
All registrations	0.5%	0.6%	0.5%	0.2%	1.3%	0.3%	0.6%
Haematology	0.9%	0.8%	0.9%	0.1%	1.9%	0.1%	0.9%
Head and Neck	0.3%	0.3%	0.3%	0.0%	1.0%	0.0%	0.3%
Lower GI	0.5%	0.7%	0.5%	0.4%	1.1%	0.5%	1.1%
Upper GI	0.7%	1.1%	0.6%	0.5%	1.9%	0.5%	1.9%
HPB	1.3%	1.7%	1.2%	0.6%	3.1%	1.2%	2.5%
Trachea, Bronchus & Lung	0.7%	1.0%	0.6%	0.4%	1.9%	0.7%	1.5%
Melanoma	0.1%	0.0%	0.1%	0.0%	0.0%	0.0%	0.0%
Breast	0.3%	0.3%	0.3%	0.1%	0.7%	0.1%	0.1%
Cervix	0.2%	0.4%	0.2%	0.5%	0.0%	1.2%	0.0%
Other Female Genitals	0.6%	0.7%	0.6%	0.3%	1.4%	0.2%	1.1%
Prostate	0.5%	0.4%	0.5%	0.2%	0.9%	0.1%	0.4%
Kidney	0.7%	0.8%	0.6%	0.4%	1.3%	0.0%	1.8%
Bladder	0.9%	0.7%	0.9%	0.1%	1.3%	0.0%	1.0%
Brain and CNS	0.9%	0.9%	0.8%	0.5%	1.1%	0.0%	2.1%
Thyroid & other endocrine glands	0.3%	0.5%	0.3%	0.0%	0.8%	1.1%	0.4%
CUP	5.2%	6.2%	5.0%	2.7%	12.4%	4.9%	5.9%
Other invasive cancer	1.4%	2.3%	1.1%	1.2%	4.5%	2.6%	2.2%
Breast in situ	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Cervix in situ	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Other tumours	0.6%	0.4%	0.8%	0.1%	1.1%	0.0%	0.0%

4: % Zero survival

Percentage (%) of zero survival cases (persons)

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Wales	Northern Ireland	Republic of Ireland
All invasive xnmsc	1.4%	1.3%	1.5%	0.8%	2.2%	0.6%	1.6%
All xnmsc 0-24	0.3%	0.3%	0.3%	0.3%	0.0%	0.0%	1.0%
All xnmsc 25-59	0.3%	0.3%	0.4%	0.2%	0.4%	0.2%	0.3%
All xnmsc 60-79	1.0%	0.9%	1.0%	0.7%	1.3%	0.6%	1.1%
All xnmsc 80+	3.9%	3.8%	3.9%	1.7%	6.0%	1.4%	6.0%
All registrations	1.0%	0.9%	1.0%	0.5%	1.6%	0.3%	0.9%
Haematology	1.6%	1.5%	1.7%	0.4%	2.8%	0.6%	1.7%
Head and Neck	0.5%	0.5%	0.5%	0.0%	1.2%	0.0%	0.7%
Lower GI	1.3%	1.2%	1.4%	0.7%	1.5%	0.6%	1.8%
Upper GI	1.7%	1.5%	1.7%	0.8%	2.5%	0.5%	2.1%
HPB	2.9%	2.7%	3.0%	1.4%	3.8%	1.0%	4.0%
Trachea, Bronchus & Lung	2.1%	1.9%	2.3%	1.1%	2.7%	1.2%	2.3%
Melanoma	0.1%	0.0%	0.1%	0.0%	0.1%	0.0%	0.0%
Breast	0.4%	0.4%	0.4%	0.2%	0.9%	0.1%	0.2%
Cervix	0.4%	0.7%	0.4%	0.5%	0.0%	2.5%	0.0%
Other Female Genitals	1.1%	1.0%	1.1%	0.4%	1.7%	0.2%	1.6%
Prostate	0.7%	0.6%	0.7%	0.2%	1.1%	0.1%	0.9%
Kidney	1.5%	1.2%	1.6%	1.4%	1.1%	0.0%	2.1%
Bladder	1.5%	1.0%	1.6%	0.6%	1.4%	0.0%	1.6%
Brain and CNS	1.4%	1.3%	1.4%	0.7%	1.4%	0.0%	3.2%
Thyroid & other endocrine glands	0.8%	1.0%	0.7%	1.0%	0.8%	1.1%	1.4%
CUP	8.3%	8.3%	8.4%	5.1%	14.1%	5.5%	8.4%
Other invasive cancer	2.5%	3.2%	2.4%	1.8%	5.8%	3.0%	2.8%
Breast in situ	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Cervix in situ	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Other tumours	1.0%	0.6%	1.3%	0.2%	1.5%	0.1%	0.0%

5: Microscopically verified

Percentage (%) of microscopically verified cases (persons)

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Wales	Northern Ireland	Republic of Ireland
All invasive xnmsc	85.4%	85.8%	85.4%	84.2%	80.4%	86.7%	92.1%
All xnmsc 0-24	92.7%	89.3%	94.2%	97.7%	86.8%	94.9%	72.7%
All xnmsc 25-59	96.2%	96.0%	96.2%	96.5%	92.0%	97.4%	98.1%
All xnmsc 60-79	89.2%	89.1%	89.3%	87.7%	83.8%	90.3%	94.7%
All xnmsc 80+	64.0%	64.4%	64.1%	60.6%	61.0%	62.5%	73.7%
All registrations	90.0%	88.9%	90.2%	89.7%	78.6%	90.5%	95.3%
Haematology	86.7%	87.6%	86.2%	95.6%	74.9%	88.9%	92.4%
Head and Neck	97.2%	97.0%	97.3%	97.0%	96.1%	98.3%	96.1%
Lower GI	89.3%	90.0%	89.1%	88.8%	84.4%	93.0%	94.9%
Upper GI	92.7%	91.4%	93.1%	92.5%	86.1%	90.8%	94.4%
HPB	52.1%	54.6%	51.9%	44.4%	50.2%	58.7%	67.6%
Trachea, Bronchus & Lung	71.0%	72.6%	70.8%	66.3%	69.5%	71.0%	85.5%
Melanoma	99.5%	99.4%	99.5%	100.0%	97.4%	100.0%	99.8%
Breast	98.5%	98.4%	98.5%	98.5%	96.6%	99.4%	99.2%
Cervix	98.1%	97.2%	98.4%	97.6%	96.7%	96.3%	97.0%
Other Female Genitals	94.0%	92.9%	94.4%	92.5%	89.3%	95.5%	92.8%
Prostate	87.1%	88.6%	86.4%	89.0%	84.5%	86.4%	96.6%
Kidney	74.6%	76.3%	74.0%	78.7%	62.9%	80.8%	84.9%
Bladder	90.1%	89.5%	90.4%	88.1%	85.4%	89.7%	93.7%
Brain and CNS	70.8%	70.1%	70.8%	70.6%	61.5%	69.3%	78.4%
Thyroid & other endocrine glands	96.1%	93.8%	96.7%	96.0%	88.8%	95.4%	92.2%
CUP	48.4%	46.7%	48.9%	46.7%	30.0%	41.7%	66.0%
Other invasive cancer	86.4%	83.6%	87.7%	78.7%	74.6%	85.0%	92.0%
Breast in situ	99.9%	99.5%	100.0%	100.0%	97.9%	100.0%	99.8%
Cervix in situ	99.9%	99.7%	100.0%	100.0%	98.3%	100.0%	100.0%
Other tumours	87.4%	83.0%	88.7%	92.9%	51.2%	85.7%	96.5%

Percentage (%) of non-specificity of morphology codes for cases which are microscopically verified

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Wales	Northern Ireland	Republic of Ireland
All invasive xnmsc	2.0%	3.7%	1.5%	1.5%	11.0%	1.5%	2.8%
All xnmsc 0-24	2.6%	8.4%	1.0%	0.7%	37.6%	0.9%	1.9%
All xnmsc 25-59	1.4%	2.8%	0.9%	0.8%	9.3%	0.7%	2.4%
All xnmsc 60-79	1.9%	3.4%	1.4%	1.5%	9.9%	1.6%	2.8%
All xnmsc 80+	3.5%	5.5%	2.9%	2.6%	15.5%	2.6%	4.1%
All registrations	1.5%	3.1%	1.1%	1.1%	8.7%	2.7%	1.7%
Haematology	5.3%	21.3%	0.8%	0.6%	97.3%	1.2%	6.4%
Head and Neck	1.9%	1.9%	1.9%	1.7%	1.2%	2.0%	3.0%
Lower GI	1.0%	1.2%	0.9%	0.4%	3.0%	0.5%	1.2%
Upper GI	1.9%	2.2%	1.8%	1.6%	3.4%	1.6%	2.4%
HPB	6.4%	7.8%	5.9%	6.7%	15.2%	5.2%	6.3%
Trachea, Bronchus & Lung	3.2%	3.6%	3.0%	2.7%	5.1%	1.4%	5.8%
Melanoma	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Breast	1.0%	1.3%	0.9%	1.5%	1.2%	2.0%	1.2%
Cervix	1.1%	1.2%	1.1%	0.3%	1.4%	1.3%	2.2%
Other Female Genitals	1.3%	1.7%	1.2%	0.7%	3.0%	0.8%	2.9%
Prostate	0.5%	0.7%	0.4%	0.3%	2.0%	0.3%	0.5%
Kidney	1.3%	1.8%	1.2%	1.7%	2.0%	1.5%	2.7%
Bladder	0.9%	1.5%	0.8%	0.1%	1.9%	2.1%	2.6%
Brain and CNS	0.5%	0.7%	0.5%	0.7%	1.8%	0.0%	0.7%
Thyroid & other endocrine glands	2.4%	2.2%	2.4%	1.0%	1.8%	1.2%	4.6%
CUP	19.4%	19.9%	19.5%	15.8%	30.6%	14.7%	19.1%
Other invasive cancer	1.5%	2.7%	1.1%	0.8%	3.0%	3.5%	5.0%
Breast in situ	0.2%	0.2%	0.2%	0.2%	0.0%	0.4%	0.2%
Cervix in situ	0.1%	0.2%	0.1%	0.0%	0.5%	0.0%	0.2%
Other tumours	3.5%	6.6%	2.9%	2.1%	16.1%	12.0%	0.0%

6: Mortality : Incidence ratios

Mortality : Incidence ratios

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Wales	Northern Ireland	Republic of Ireland
All invasive xnmsc	0.45	0.46	0.45	0.51	0.46	0.46	0.42
All xnmsc 0-24	0.12	0.11	0.12	0.11	0.09	0.13	0.11
All xnmsc 25-59	0.24	0.25	0.23	0.28	0.24	0.24	0.23
All xnmsc 60-79	0.42	0.44	0.42	0.49	0.43	0.45	0.41
All xnmsc 80+	0.78	0.80	0.77	0.84	0.75	0.80	0.84
All registrations	0.28	0.28	0.28	0.31	0.31	0.25	0.23
Haematology	0.41	0.44	0.40	0.48	0.40	0.49	0.42
Head and Neck	0.32	0.35	0.31	0.35	0.30	0.38	0.38
Lower GI	0.38	0.39	0.37	0.42	0.41	0.35	0.38
Upper GI	0.77	0.78	0.77	0.82	0.81	0.76	0.75
HPB	0.84	0.84	0.84	0.87	0.80	0.81	0.86
Trachea, Bronchus & Lung	0.77	0.78	0.76	0.81	0.77	0.78	0.79
Melanoma	0.15	0.15	0.16	0.13	0.17	0.15	0.14
Breast	0.21	0.21	0.21	0.21	0.22	0.20	0.24
Cervix	0.28	0.31	0.26	0.31	0.40	0.22	0.35
Other Female Genitals	0.39	0.40	0.38	0.44	0.39	0.37	0.43
Prostate	0.24	0.24	0.25	0.32	0.22	0.23	0.16
Kidney	0.35	0.36	0.34	0.39	0.33	0.37	0.38
Bladder	0.53	0.55	0.53	0.64	0.47	0.56	0.54
Brain and CNS	0.77	0.80	0.75	1.00	0.77	0.77	0.73
Thyroid & other endocrine glands	0.15	0.16	0.14	0.16	0.16	0.18	0.14
CUP	1.14	1.06	1.18	0.91	1.14	1.40	0.67
Other invasive cancer	0.78	0.76	0.78	0.83	0.75	0.88	0.54
Breast in situ	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cervix in situ	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other tumours	0.07	0.05	0.09	0.04	0.07	0.03	0.00

7: Demographics

Completeness of the dataset (%) - demographics and diagnostic details

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Wales	Northern Ireland	Republic of Ireland
Patient's name	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Patient's address	99.7%	99.6%	99.7%	100.0%	100.0%	100.0%	98.2%
Sex	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Ethnicity	86.2%	62.5%	91.8%	67.8%	28.0%	NA	NA
Date of death (where dead)	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%
Postcode	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	NA
Date of birth	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Unique health identifier	99.9%	100.0%	99.9%	100.0%	100.0%	99.9%	NA
Anniversary (diagnosis) date	100.0%	100.0%	99.9%	100.0%	100.0%	100.0%	100.0%
Site of primary growth	97.5%	97.5%	97.6%	97.1%	97.1%	98.2%	97.7%
Type of growth	89.0%	86.2%	90.0%	88.4%	71.5%	88.0%	93.1%
Behaviour of growth	99.9%	99.9%	100.0%	99.7%	99.7%	99.9%	100.0%
Basis of diagnosis	99.2%	98.8%	99.4%	99.9%	98.9%	99.2%	96.8%
Diagnosis with hospital	97.4%	96.1%	97.9%	93.2%	98.3%	95.5%	95.8%

8A: Treatment

% of all cancer cases (xnmsc)

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Wales	Northern Ireland	Republic of Ireland
Treatment	83.3%	74.0%	87.5%	69.8%	57.3%	90.6%	64.8%
No Treatment	6.3%	11.4%	2.4%	29.9%	NA	0.2%	13.0%
Stage I and II patients receiving any treatment (%)	93.2%	88.0%	94.6%	86.8%	81.3%	93.1%	84.3%

8B: Treatment - surgery

% of Cases treated with Surgery

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Wales	Northern Ireland	Republic of Ireland
All invasive xnmsc	46.7%	45.2%	47.7%	42.1%	38.7%	54.3%	43.1%
All xnmsc 0-24	48.5%	47.7%	49.2%	49.4%	47.3%	55.1%	37.4%
All xnmsc 25-59	63.6%	61.1%	64.9%	60.5%	54.7%	69.5%	56.0%
All xnmsc 60-79	46.5%	44.5%	47.7%	41.0%	39.0%	54.0%	40.6%
All xnmsc 80+	28.9%	27.8%	29.7%	23.5%	22.7%	35.3%	27.7%
Haematology	6.0%	8.4%	5.3%	3.8%	14.1%	9.2%	9.7%
Head and Neck	52.0%	49.6%	53.5%	44.2%	47.9%	53.6%	48.7%
Lower GI	65.5%	66.0%	66.0%	64.9%	56.8%	82.8%	59.5%
Upper GI	32.9%	27.6%	36.5%	15.4%	10.6%	49.0%	26.4%
HPB	29.3%	26.3%	31.7%	13.3%	10.8%	45.4%	30.0%
Trachea, Bronchus & Lung	22.2%	19.7%	23.8%	13.1%	16.1%	27.7%	17.9%
Melanoma	92.3%	90.9%	92.5%	98.1%	85.8%	89.6%	88.6%
Breast	75.9%	74.5%	76.7%	76.6%	70.7%	84.5%	64.2%
Cervix	58.6%	50.9%	64.2%	26.9%	44.0%	61.7%	57.4%
Other Female Genitals	72.3%	68.5%	73.8%	69.9%	57.6%	74.5%	66.9%
Prostate	21.5%	18.6%	22.3%	15.8%	14.3%	17.8%	22.9%
Kidney	59.3%	59.2%	59.9%	55.2%	48.8%	75.5%	56.8%
Bladder	81.6%	75.3%	84.0%	77.4%	77.3%	87.8%	50.0%
Brain and CNS	48.3%	51.7%	47.1%	55.1%	38.1%	58.4%	59.6%
Thyroid & other endocrine glands	79.1%	75.4%	80.6%	77.7%	65.6%	86.2%	67.1%
CUP	13.1%	11.7%	14.4%	6.8%	8.0%	19.6%	9.5%
Other invasive cancer	51.1%	49.1%	52.4%	45.4%	42.0%	56.8%	48.7%
Breast in situ	85.0%	84.4%	85.5%	94.2%	77.1%	95.8%	69.4%
Cervix in situ	82.3%	63.7%	87.9%	85.3%	58.5%	13.3%	73.4%
Other tumours	58.8%	54.4%	60.4%	60.9%	39.4%	47.6%	63.3%
Non-Melanoma Skin Cancer	50.7%	71.1%	43.1%	89.5%	85.3%	56.4%	80.9%

8C: Treatment - radiotherapy

% of Cases treated with Radiotherapy

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Wales	Northern Ireland	Republic of Ireland
All invasive xnmsc	19.5%	18.7%	20.0%	20.1%	10.9%	25.5%	17.0%
All xnmsc 0-24	12.9%	12.1%	13.5%	10.0%	7.3%	20.3%	9.1%
All xnmsc 25-59	22.2%	21.7%	22.6%	24.0%	13.4%	29.8%	18.9%
All xnmsc 60-79	21.8%	20.5%	22.5%	22.1%	12.0%	28.0%	18.0%
All xnmsc 80+	11.4%	10.6%	11.8%	10.7%	6.2%	13.5%	10.9%
Haematology	8.7%	8.0%	9.1%	8.2%	3.6%	11.7%	7.5%
Head and Neck	54.8%	52.2%	56.6%	48.7%	38.5%	66.6%	50.4%
Lower GI	12.4%	11.8%	12.6%	11.6%	8.5%	13.3%	13.0%
Upper GI	17.7%	16.6%	17.9%	16.2%	11.4%	12.1%	25.3%
HPB	2.3%	2.9%	2.2%	2.3%	1.1%	4.9%	3.9%
Trachea, Bronchus & Lung	26.8%	25.7%	27.1%	30.1%	17.6%	31.9%	21.7%
Melanoma	0.9%	1.2%	0.9%	0.4%	1.3%	2.0%	1.3%
Breast	35.1%	33.4%	36.0%	38.4%	14.0%	50.0%	28.6%
Cervix	39.6%	42.7%	38.1%	49.1%	29.3%	54.3%	42.6%
Other Female Genitals	14.3%	15.1%	14.1%	15.2%	14.0%	18.2%	13.8%
Prostate	17.1%	14.5%	18.5%	10.7%	5.8%	26.0%	11.3%
Kidney	5.2%	5.2%	5.2%	5.7%	4.4%	6.5%	4.2%
Bladder	15.4%	14.2%	15.9%	14.7%	11.6%	19.7%	9.1%
Brain and CNS	43.2%	43.9%	43.1%	42.2%	28.1%	54.7%	51.5%
Thyroid & other endocrine glands	29.7%	25.5%	31.8%	25.0%	18.4%	39.1%	13.1%
CUP	11.2%	9.9%	11.9%	8.2%	6.1%	12.9%	10.5%
Other invasive cancer	15.2%	12.3%	16.3%	12.5%	8.4%	13.5%	10.8%
Breast in situ	29.5%	30.7%	29.1%	38.6%	15.2%	38.0%	32.8%
Cervix in situ	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%
Other tumours	1.0%	1.1%	1.1%	0.4%	0.6%	2.9%	0.7%
Non-Melanoma Skin Cancer	1.0%	1.2%	1.1%	0.5%	1.7%	1.7%	0.9%

8D: Treatment - teletherapy

% of Cases treated with Teletherapy

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Wales	Northern Ireland	Republic of Ireland
All invasive xnmsc	17.0%	19.0%	16.8%	NA	NA	23.8%	16.3%
All xnmsc 0-24	10.0%	11.3%	9.9%	NA	NA	15.3%	8.7%
All xnmsc 25-59	17.5%	20.6%	17.2%	NA	NA	26.6%	18.0%
All xnmsc 60-79	19.3%	21.0%	19.2%	NA	NA	26.6%	17.1%
All xnmsc 80+	11.1%	11.7%	11.1%	NA	NA	13.3%	10.8%
Haematology	8.8%	9.3%	8.8%	NA	NA	11.7%	7.5%
Head and Neck	40.3%	51.9%	38.6%	NA	NA	66.6%	50.4%
Lower GI	7.6%	11.1%	7.0%	NA	NA	13.3%	13.0%
Upper GI	14.5%	17.1%	13.8%	NA	NA	12.1%	25.3%
HPB	1.9%	3.4%	1.7%	NA	NA	4.5%	3.9%
Trachea, Bronchus & Lung	25.5%	26.4%	25.5%	NA	NA	31.9%	21.7%
Melanoma	0.9%	1.4%	0.9%	NA	NA	2.0%	1.2%
Breast	35.5%	38.0%	35.6%	NA	NA	50.0%	28.5%
Prostate	19.0%	21.1%	17.5%	NA	NA	6.2%	39.6%
Cervix	8.7%	7.8%	8.8%	NA	NA	6.7%	7.9%
Other Female Genitals	16.0%	16.3%	16.4%	NA	NA	23.4%	9.3%
Kidney	4.9%	5.2%	4.9%	NA	NA	6.5%	4.2%
Bladder	14.0%	14.3%	14.2%	NA	NA	19.7%	9.1%
Brain and CNS	31.6%	45.2%	29.3%	NA	NA	54.7%	51.5%
Thyroid & other endocrine glands	7.6%	7.7%	7.7%	NA	NA	10.3%	4.9%
CUP	10.5%	11.3%	10.4%	NA	NA	12.9%	10.5%
Other invasive cancer	12.5%	12.3%	12.6%	NA	NA	13.5%	10.7%
Breast in situ	29.5%	33.3%	29.0%	NA	NA	38.0%	32.8%
Cervix in situ	0.0%	0.1%	0.0%	NA	NA	0.1%	0.1%
Other tumours	1.0%	1.5%	0.9%	NA	NA	2.9%	0.7%
Non-Melanoma Skin Cancer	1.0%	1.2%	1.0%	NA	NA	1.7%	0.8%

8E: Treatment - chemotherapy

% of Cases treated with Chemotherapy

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Wales	Northern Ireland	Republic of Ireland
All invasive xnmsc	25.8%	23.7%	26.5%	26.2%	20.3%	25.7%	19.8%
All xnmsc 0-24	56.7%	48.3%	60.3%	60.6%	51.7%	55.1%	14.0%
All xnmsc 25-59	39.4%	37.0%	40.4%	43.2%	33.5%	40.9%	27.1%
All xnmsc 60-79	26.4%	23.7%	27.3%	25.8%	21.1%	24.5%	19.6%
All xnmsc 80+	7.8%	6.7%	8.2%	6.3%	4.7%	7.3%	6.9%
Haematology	51.5%	46.8%	52.9%	58.6%	34.3%	52.8%	35.5%
Head and Neck	28.9%	25.2%	30.4%	25.6%	28.8%	24.6%	16.6%
Lower GI	31.5%	28.5%	32.5%	30.0%	24.7%	28.5%	26.8%
Upper GI	38.8%	35.7%	40.4%	36.6%	30.5%	43.3%	28.0%
HPB	23.6%	21.3%	24.7%	19.9%	15.8%	26.5%	19.5%
Trachea, Bronchus & Lung	28.1%	24.9%	29.4%	23.4%	24.2%	24.0%	23.4%
Melanoma	1.1%	1.2%	1.1%	0.4%	2.2%	1.0%	1.5%
Breast	31.7%	31.0%	31.9%	33.3%	25.9%	33.4%	30.6%
Cervix	34.7%	35.1%	34.6%	43.0%	26.0%	49.4%	22.6%
Other Female Genitals	29.2%	28.6%	29.3%	33.9%	22.2%	32.4%	25.2%
Prostate	3.2%	3.1%	3.2%	5.6%	3.7%	2.6%	0.4%
Kidney	8.4%	8.0%	8.6%	4.0%	9.7%	8.0%	9.9%
Bladder	29.7%	25.2%	31.1%	28.7%	22.9%	28.2%	15.0%
Brain and CNS	27.1%	23.4%	28.4%	33.5%	11.5%	29.9%	13.5%
Thyroid & other endocrine glands	4.7%	4.6%	4.8%	4.7%	5.6%	4.6%	3.5%
CUP	11.8%	8.7%	12.9%	7.7%	5.3%	5.5%	12.0%
Other invasive cancer	28.8%	24.2%	30.6%	25.6%	21.1%	26.3%	17.3%
Breast in situ	1.3%	1.3%	1.4%	0.6%	0.0%	3.8%	0.9%
Cervix in situ	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%	0.0%
Other tumours	11.1%	8.3%	12.7%	11.3%	5.3%	9.2%	3.2%
Non-Melanoma Skin Cancer	0.1%	0.4%	0.1%	0.6%	0.2%	0.9%	0.1%

8F: Treatment - other

% of Cases for other treatments

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Wales	Northern Ireland	Republic of Ireland
% of Cases treated with Hormone Therapy
All invasive xnmsc	12.1%	11.9%	12.4%	14.9%	5.4%	20.6%	6.1%
Breast	39.9%	42.6%	39.1%	61.7%	17.3%	70.3%	24.6%
Prostate	43.2%	38.7%	45.7%	52.1%	20.4%	60.3%	14.9%
% of Cases treated with Brachytherapy
All invasive xnmsc	0.9%	1.2%	0.9%	NA	NA	1.7%	1.1%
Breast	0.0%	0.1%	0.0%	NA	NA	0.0%	0.2%
Prostate	2.4%	2.5%	2.3%	NA	NA	3.0%	2.2%
% of Cases treated with Watch & Wait/Active Monitoring
All invasive xnmsc	8.0%	5.6%	8.5%	NA	NA	7.0%	1.3%
Prostate	24.2%	17.4%	25.8%	NA	NA	22.1%	4.2%
% of Cases treated with Palliative Care
All invasive xnmsc	8.0%	6.1%	8.5%	NA	NA	8.3%	1.6%

8G: Treatment - cohorts

Specific cohorts where treatment completeness data is expected (%)

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Wales	Northern Ireland	Republic of Ireland
% of children and young adults (0-24 group) with cancer & underwent any treatment	91.5%	86.2%	93.8%	92.3%	79.0%	95.8%	69.9%
% of men under 60 with prostate cancer & received hormone treatment	19.7%	19.6%	21.3%	28.6%	11.6%	32.0%	4.4%
% of men under 60 with cancer (C00-C97 exc. C44) & received hormone treatment	3.6%	3.6%	3.7%	4.2%	1.8%	6.9%	1.2%
% of women under 60 with breast cancer & received hormone treatment	25.9%	31.2%	24.3%	46.8%	8.2%	57.9%	18.7%
% of all haematological cancer patients who received any treatment	77.6%	64.3%	82.5%	63.9%	45.2%	77.0%	53.0%

8H: Treatment - quality of data

Quality of treatment data

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Wales	Northern Ireland	Republic of Ireland
Surgery (denominator - all tumours known to be treated with surgery, first recorded surgery for that tumour):
Date of surgery known	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Trust / hospital of surgery known	99.8%	99.9%	99.8%	100.0%	100.0%	100.0%	99.7%
Type of surgery known (OPCS4 code)	99.8%	98.2%	100.0%	NA	100.0%	92.6%	100.0%
Teletherapy (denominator - all tumours known to be treated with teletherapy , first recorded teletherapy treatment for that tumour):
Date of teletherapy known	100.0%	100.0%	100.0%	NA	NA	100.0%	100.0%
Trust / hospital of teletherapy known	99.9%	100.0%	99.9%	NA	NA	100.0%	99.9%
Fractions and dose known	97.3%	97.3%	NA	NA	NA	97.3%	NA
Chemotherapy (denominator - all tumours known to be treated with chemotherapy, first recorded chemotherapy treatment for that tumour):
Date of chemotherapy known	100.0%	100.0%	99.9%	100.0%	100.0%	100.0%	100.0%
Trust / hospital of chemotherapy known	99.8%	99.9%	99.7%	100.0%	100.0%	100.0%	99.9%
Drug name or regimen known	75.5%	66.2%	NA	NA	NA	33.2%	99.2%
Radiotherapy (denominator - all tumours known to be treated with radiotherapy, take the first recorded radiotherapy event for that tumour):
Date of radiotherapy known	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Trust / hospital of radiotherapy known	99.9%	100.0%	99.9%	100.0%	100.0%	100.0%	99.9%

9A: Dataset - breast screening

Breast cancer screening completeness (%)

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Wales	Northern Ireland	Republic of Ireland
Breast cancer - % screen detected for ages 50-64 (data 2015)	37.8%	43.0%	36.1%	51.2%	23.9%	49.0%	54.6%
Breast cancer - % screen detected for ages 50-64 (last year, 2014)	48.0%	50.7%	47.1%	48.1%	51.5%	51.4%	55.2%
Breast cancer - % with full screening history for ages 50-64 (data 2015)	72.8%	76.9%	71.0%	99.9%	38.8%	97.1%	77.9%
Breast cancer - % with full screening history for ages 50-64 (last year, 2014)	89.1%	91.1%	88.4%	99.9%	87.7%	98.1%	81.7%

9B: Dataset - cervical screening

Cervical cancer screening completeness (%)

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Wales	Northern Ireland	Republic of Ireland
Cervical cancer - % screen detected for ages 25-60 (data 2015)	11.6%	20.0%	6.8%	45.3%	NA	7.9%	NA
Cervical cancer - % screen detected for ages 25-60 (last year, 2014)	19.2%	30.0%	13.8%	54.4%	NA	21.9%	NA
Cervical cancer - % with full screening history for ages 25-60 (data 2015)	29.8%	66.8%	17.8%	100.0%	NA	82.5%	NA
Cervical cancer - % with full screening history for ages 25-60 (last year, 2014)	39.6%	76.0%	28.5%	99.7%	NA	100.0%	NA

9C: Dataset - bowel screening

Bowel cancer screening completeness (%)

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Wales	Northern Ireland	Republic of Ireland
Bowel cancer - % screen detected for ages 60-69 (data 2015)	4.3%	18.4%	0.0%	27.4%	19.1%	27.0%	NA
Bowel cancer - % screen detected for ages 60-69 (last year, 2014)	18.8%	23.7%	17.0%	29.7%	21.2%	26.9%	NA
Bowel cancer - % with full screening history for ages 60-69 (data 2015)	15.2%	65.0%	0.0%	99.7%	63.7%	96.5%	NA
Bowel cancer - % with full screening history for ages 60-69 (last year, 2014)	71.9%	83.5%	68.1%	99.9%	67.1%	99.0%	NA

9D: Dataset - stage complete

Completeness of the dataset (%) - stage complete by cancer site groups summary (persons)

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Wales	Northern Ireland	Republic of Ireland
All invasive xnmsc	76.8%	69.4%	80.4%	60.8%	65.1%	82.4%	58.1%
Haematology	57.1%	27.5%	68.6%	0.0%	0.0%	68.9%	0.0%
Head and Neck	77.5%	65.8%	87.7%	0.0%	84.1%	96.1%	60.9%
Lower GI	86.9%	81.6%	89.7%	73.2%	81.1%	92.2%	71.9%
Upper GI	78.2%	69.6%	82.1%	62.6%	78.3%	70.8%	54.2%
HPB	67.7%	65.1%	68.9%	65.6%	54.7%	74.6%	61.5%
Trachea, Bronchus & Lung	89.6%	84.2%	91.5%	90.3%	84.9%	92.2%	62.3%
Melanoma	88.4%	79.5%	93.7%	40.9%	78.1%	97.8%	86.8%
Breast	90.4%	84.9%	92.8%	84.3%	76.6%	95.7%	75.2%
Cervix	81.4%	83.4%	80.6%	91.8%	80.7%	96.3%	67.7%
Other Female Genitals	82.9%	74.0%	86.5%	70.2%	69.1%	81.8%	62.3%
Prostate	87.0%	79.9%	90.1%	77.9%	77.2%	91.4%	63.0%
Bladder	81.3%	70.9%	86.1%	53.9%	64.8%	89.2%	60.5%
Kidney	82.9%	77.4%	85.6%	65.4%	72.4%	91.4%	72.1%
Thyroid and other endocrine glands	65.6%	64.8%	69.6%	0.0%	86.2%	98.8%	69.6%
Other invasive cancer	56.4%	46.6%	61.3%	19.0%	35.3%	70.3%	47.1%
Non-Melanoma Skin Cancer	6.5%	8.5%	6.8%	0.0%	13.6%	20.0%	2.0%

9E: Dataset - grade complete

Completeness of the dataset (%) - grade complete by cancer site groups summary (persons)

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Wales	Northern Ireland	Republic of Ireland
All invasive xnmsc	58.9%	55.1%	60.3%	58.5%	40.3%	61.0%	55.2%
All xnmsc 0-24	29.9%	26.8%	30.8%	39.3%	9.3%	31.4%	23.1%
All xnmsc 25-59	65.9%	61.9%	67.4%	67.0%	48.7%	68.7%	58.0%
All xnmsc 60-79	63.2%	58.7%	64.9%	62.7%	42.0%	65.5%	58.4%
All xnmsc 80+	42.2%	38.9%	43.4%	38.6%	29.7%	40.8%	41.9%
All registrations	45.2%	41.5%	45.8%	NA	NA	NA	37.2%
Haematology	15.8%	21.5%	13.9%	41.2%	1.3%	10.1%	40.8%
Head and Neck	79.9%	75.3%	81.4%	83.8%	66.6%	82.0%	62.9%
Lower GI	78.9%	75.9%	80.2%	79.6%	61.6%	83.8%	74.2%
Upper GI	77.2%	71.5%	79.3%	75.4%	60.7%	71.3%	70.9%
HPB	27.7%	25.8%	28.6%	23.0%	16.0%	27.8%	33.5%
Trachea, Bronchus & Lung	28.7%	27.6%	29.4%	26.8%	20.3%	32.1%	29.4%
Melanoma	1.0%	0.7%	1.1%	0.1%	0.6%	0.0%	1.9%
Breast	94.1%	89.4%	96.0%	88.4%	87.7%	94.6%	80.0%
Cervix	79.3%	73.7%	82.0%	80.5%	82.0%	76.5%	47.7%
Other Female Genitals	75.0%	71.9%	76.2%	74.4%	64.4%	81.6%	62.9%
Prostate	79.9%	71.0%	83.0%	86.6%	26.8%	82.8%	75.9%
Bladder	84.7%	77.0%	87.4%	83.6%	65.0%	88.7%	60.5%
Kidney	59.5%	52.1%	61.8%	61.5%	12.1%	71.7%	53.4%
Brain and CNS	68.4%	64.1%	70.3%	69.0%	14.4%	91.2%	75.5%
Thyroid and other endocrine glands	18.7%	15.4%	20.0%	9.7%	21.1%	15.0%	11.3%
CUP	22.4%	19.0%	23.3%	21.9%	9.7%	13.5%	26.7%
Other invasive cancer	30.4%	27.2%	31.6%	30.9%	10.4%	38.9%	24.2%
Other tumours	41.8%	28.5%	44.0%	NA	NA	12.9%	NA
Non-Melanoma Skin Cancer	17.5%	19.8%	16.3%	26.1%	31.2%	3.7%	21.8%